Joan J. Ryoo
- Hematology top 2%
- Multiple Myeloma Research and Treatments 3
- Oncology top 10%
- Global Cancer Incidence and Screening 4
- Colorectal Cancer Screening and Detection 2
- Colorectal Cancer Surgical Treatments 2
- Genetics top 10%
-
- Cancer therapeutics and mechanisms 3
-
- Palliative Care and End-of-Life Issues 4
-
- Brain Metastases and Treatment 3
-
- Economic and Financial Impacts of Cancer 3
- Co-authors
- Kenneth C. AndersonTeru HideshimaAndrea FreemanFaith E. DaviesLaurence CatleyRebecca L. RichEdie WellerDeborah Doss
- Cited by
- HematologyOncologyGenetics
- Journals
- Journal of Clinical Oncology (2 papers)Blood (2 papers)International Journal of Radiation Oncology*Biology*Physics (2 papers)
- Partner nations
- United StatesAustralia
In The Last Decade
Joan J. Ryoo
18 papers receiving 837 citations
Hit Papers
Peers
Comparison fields: 5 of 59
- Hematology 572
- Oncology 427
- Genetics 107
- Molecular Biology 476
- Geriatrics and Gerontology 20
Countries citing papers authored by Joan J. Ryoo
This map shows the geographic impact of Joan J. Ryoo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joan J. Ryoo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joan J. Ryoo more than expected).
Fields of papers citing papers by Joan J. Ryoo
This network shows the impact of papers produced by Joan J. Ryoo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joan J. Ryoo. The network helps show where Joan J. Ryoo may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Joan J. Ryoo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 1 | |
| 2 | 2021 | 0 | |
| 3 | 2020 | 20 | |
| 4 | 2019 | 1 | |
| 5 | 2019 | 5 | |
| 6 | 2017 | 14 | |
| 7 | 2015 | 1 | |
| 8 | 2014 | 13 | |
| 9 | 2014 | 2 | |
| 10 | Validating electronic cancer quality measures at Veterans Health Administration. | 2014 | 9 |
| 11 | 2013 | 28 | |
| 12 | 2010 | 69 | |
| 13 | 2009 | 12 | |
| 14 | 2008 | 3 | |
| 15 | 2005 | 34 | |
| 16 | 2005 | 1 | |
| 17 | 2002 | 6 | |
| 18 | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomabreakdown → | 2002 | 630 |
| 19 | A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM). | 2001 | 23 |
About Joan J. Ryoo
Joan J. Ryoo is a scholar working on Otorhinolaryngology, Oncology and Hematology, having authored 19 papers that have together received 872 indexed citations. Recurring topics across this work include Global Cancer Incidence and Screening (4 papers), Palliative Care and End-of-Life Issues (4 papers), Multiple Myeloma Research and Treatments (3 papers), Brain Metastases and Treatment (3 papers), Cancer therapeutics and mechanisms (3 papers), Economic and Financial Impacts of Cancer (3 papers), Colorectal Cancer Screening and Detection (2 papers) and Colorectal Cancer Surgical Treatments (2 papers). The work is most often cited by research in Hematology (572 citations), Oncology (427 citations) and Genetics (107 citations). Joan J. Ryoo has collaborated with scholars based in United States and Australia. Frequent co-authors include Kenneth C. Anderson, Teru Hideshima, Andrea Freeman, Faith E. Davies, Laurence Catley, Rebecca L. Rich, Edie Weller, Deborah Doss, Jerome B. Zeldis and Richard LeBlanc. Their work appears in journals such as Journal of Clinical Oncology, Blood and International Journal of Radiation Oncology*Biology*Physics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.